Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04993677 · ClinicalTrials.gov registry record · Phase 2
A Study of SEA-CD40 Given With Other Drugs in Cancers
A Phase 2 study, sponsored by Seagen.
- Completed
- Registry status
- Phase 2
- Development phase
- 77
- Enrollment target
NCT04993677 is a Phase 2 study that has completed, run by Seagen. The registered enrollment target is 77 participants.
The verdict
NCT04993677, a Phase 2 study, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 77 participants
- Enrollment target
Study Summary
This trial is being done to see if an experimental drug (SEA-CD40) works when it's given with other cancer drugs to treat some types of cancer. It will also study side effects from the drug. There are 2 parts in this trial. In one part, participants have melanoma that has come back after treatment or can't be removed by surgery. Participants in this part will get SEA-CD40 and pembrolizumab. In the other part, participants have non-small cell lung cancer (NSCLC) that has spread through their body. These participants will get SEA-CD40, pembrolizumab, carboplatin, and pemetrexed.
Interventions
- DRUG carboplatin
- DRUG pemetrexed
- DRUG pembrolizumab (KEYTRUDA®)
- DRUG SEA-CD40
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2021-10-06 |
| Est. Completion | 2024-11-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04993677
The ClinicalTrials.gov registry entry for NCT04993677 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which carboplatin is the first listed.
NCT04993677 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04993677 about?
NCT04993677 is a clinical study titled "A Study of SEA-CD40 Given With Other Drugs in Cancers". This trial is being done to see if an experimental drug (SEA-CD40) works when it's given with other cancer drugs to treat some types of cancer. It will also study side effects from the drug. There are 2 parts in this trial. In one part, participants have melanoma that has come back after treatment ...
What is the current status of trial NCT04993677?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 2021-10-06. Estimated completion is 2024-11-25.
What interventions are being tested in trial NCT04993677?
The interventions under investigation include: carboplatin (DRUG), pemetrexed (DRUG), pembrolizumab (KEYTRUDA®) (DRUG), SEA-CD40 (DRUG).
Who is sponsoring clinical trial NCT04993677?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.